Vascular endothelial growth factor receptors VEGFR-2 and VEGFR-3 are localized primarily to the vasculature in human primary solid cancers.
about
HET0016, a selective inhibitor of 20-HETE synthesis, decreases pro-angiogenic factors and inhibits growth of triple negative breast cancer in miceMolecular mechanism underlying lymphatic metastasis in pancreatic cancerRNA-Seq Differentiates Tumour and Host mRNA Expression Changes Induced by Treatment of Human Tumour Xenografts with the VEGFR Tyrosine Kinase Inhibitor CediranibKDR Mutation as a Novel Predictive Biomarker of Exceptional Response to Regorafenib in Metastatic Colorectal CancerAssessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: focus on the cancer hallmark of tumor angiogenesisActionable gene expression-based patient stratification for molecular targeted therapy in hepatocellular carcinomaVascular endothelial growth factor receptor 2 as a marker for malignant vascular tumors and mesothelioma: an immunohistochemical study of 262 vascular endothelial and 1640 nonvascular tumorsDifferential expression of VEGFR2 protein in HER2 positive primary human breast cancer: potential relevance to anti-angiogenic therapies.Animal model of naturally occurring bladder cancer: characterization of four new canine transitional cell carcinoma cell lines.Lysine methylation promotes VEGFR-2 activation and angiogenesis.Addition of bevacizumab enhances antitumor activity of erlotinib against non-small cell lung cancer xenografts depending on VEGF expression.Morpholino-Mediated Isoform Modulation of Vascular Endothelial Growth Factor Receptor-2 (VEGFR2) Reduces Colon Cancer Xenograft Growth.Dopamine D2 receptor agonists inhibit lung cancer progression by reducing angiogenesis and tumor infiltrating myeloid derived suppressor cells.T cells bearing a chimeric antigen receptor against prostate-specific membrane antigen mediate vascular disruption and result in tumor regression.Novel functional germline variants in the VEGF receptor 2 gene and their effect on gene expression and microvessel density in lung cancer.A small molecular agent YL529 inhibits VEGF-D-induced lymphangiogenesis and metastasis in preclinical tumor models in addition to its known antitumor activities.MET Suppresses Epithelial VEGFR2 via Intracrine VEGF-induced Endoplasmic Reticulum-associated DegradationVascular endothelial growth factor directly stimulates tumour cell proliferation in non-small cell lung cancer.Design, synthesis, and biological evaluation of novel FAK scaffold inhibitors targeting the FAK-VEGFR3 protein-protein interaction.A FAK scaffold inhibitor disrupts FAK and VEGFR-3 signaling and blocks melanoma growth by targeting both tumor and endothelial cellsU.S. Food and Drug Administration Approval Summary: Ramucirumab for the Treatment of Metastatic Non-Small Cell Lung Cancer Following Disease Progression On or After Platinum-Based Chemotherapy.PET Imaging of VEGFR-2 Expression in Lung Cancer with 64Cu-Labeled RamucirumabTargeting prion-like protein doppel selectively suppresses tumor angiogenesis.VEGFR-2 conformational switch in response to ligand binding.Trial watch: DNA vaccines for cancer therapy.Inhibition of Metastatic Potential in Breast Carcinoma In Vivo and In Vitro through Targeting VEGFRs and FGFRs.Distinct patterns of angiogenic factor expression as a predictive factor of response to chemotherapy in stage IIIA non-small-cell lung cancer patients.Tumor cell expression of vascular endothelial growth factor receptor 2 is an adverse prognostic factor in patients with squamous cell carcinoma of the lungBiomarker analyses in REGARD gastric/GEJ carcinoma patients treated with VEGFR2-targeted antibody ramucirumabThe FAK scaffold inhibitor C4 disrupts FAK-VEGFR-3 signaling and inhibits pancreatic cancer growth.Vasculogenic mimicry in small cell lung cancer.Stromal-epithelial crosstalk provides a suitable microenvironment for the progression of ovarian cancer cells in vitro.Circulating proteins as potential biomarkers of sunitinib and interferon-α efficacy in treatment-naïve patients with metastatic renal cell carcinoma.Tissue factor is an angiogenic-specific receptor for factor VII-targeted immunotherapy and photodynamic therapy.Visualization of angiogenesis during cancer development in the polyoma middle T breast cancer model: molecular imaging with (R)-[11C]PAQQuantitative fluorescent profiling of VEGFRs reveals tumor cell and endothelial cell heterogeneity in breast cancer xenografts.Angiogenesis and breast cancer.Progress and contrasts of the development of tivozanib for therapy of kidney cancer.Vascular endothelial growth factor signaling in acute myeloid leukemia.A call to ARMS: targeting the PAX3-FOXO1 gene in alveolar rhabdomyosarcoma.
P2860
Q21131825-F19BCD0B-4B07-475B-8BE4-764B748FAD3AQ26999345-2489D44D-9100-41BD-B3FE-BBCAC19E2D17Q27315803-454D930B-1030-465C-9604-16952D286007Q27853363-1C49874A-C4F2-44BC-A0F2-425A56F17BE9Q28397726-2559F934-8C91-4BD6-AABE-119D4732F37BQ31119684-B9C71354-D3F5-4E41-BAD8-E8B0E594F7BEQ33274369-CB0C374B-64F1-4EA0-8D18-85E87E637121Q33709284-FB208D63-026D-4416-B121-5BBF3134EF7EQ33849066-A71DB043-124B-4F9A-9D2E-A24C684CD9D7Q33940384-F10C9164-BB59-44ED-A7F0-0237D15FAC08Q34538361-443E269A-4581-49A9-A03F-9E7B37A6DE91Q34774917-A9186FA1-C785-4B3F-AE3C-06E657D06EBAQ34778819-4039FA35-BEDE-4A05-A0B1-D36EAF4D7496Q34893030-F0D79D19-DD55-4BC7-89AC-76DB5A085B29Q35166954-092C4B3F-C77E-448A-8892-659C90F1AD86Q35695806-D8CEFBE3-FCFA-492F-BFD7-4D26260B58A1Q35800730-D802F0CA-E257-4FC1-A6D0-1C6CE29B0DFCQ35939630-20137347-C478-4000-835A-1FE1EEDB326FQ36051470-4F6C54E9-D83B-441E-BF37-75FD34B3C56CQ36188833-7C6E734A-A965-4A91-9293-911AF09B0667Q36478734-34746744-3DFF-4B69-9D62-2CC83A12DBFDQ36535436-0044CF34-B077-4892-9047-446D963C14C2Q36737935-8966952C-55CE-4C19-86AD-6690F1C20161Q36791927-295C1348-2758-47C0-B231-67CA37FC76B1Q36845824-FB270D59-6BF5-4839-8ABF-377CF1DACFD1Q36938939-6C879149-D843-4DAE-9F9B-75672DE2E4EBQ37288259-0E5CF724-AC73-4C82-A876-1C229FB549FDQ37308766-11240A45-BAA6-4C88-BC52-94FBC2017635Q37335124-07D18B69-EA68-4019-93A6-B1A510CA5D4BQ37381588-4631A1F7-A05C-4BDF-A41B-8DC3C11F48AAQ37408684-6406BB7B-F275-4647-A424-40C76644884EQ37460975-AD01EE09-6EA3-4151-B3F9-051F34095A31Q37470058-8CE9B97E-8A26-4B83-86EA-0D59159DCA6CQ37639757-CDE8C14A-9245-4C07-B105-B14E9C13750BQ37703054-F04A1460-388E-407E-850E-6A4745A65626Q37703365-C64E3A5C-1947-4A58-B364-6C560CEB49F5Q37800804-6FCEF819-92F9-4492-90C0-5EDAA1B5C489Q37958038-1BA88948-E977-4E03-BD69-2043B544DEE5Q38029546-D63CDC3E-3649-422C-84A5-26821B949997Q38083828-8D7C658F-1F3B-47D8-8143-6BED17509D75
P2860
Vascular endothelial growth factor receptors VEGFR-2 and VEGFR-3 are localized primarily to the vasculature in human primary solid cancers.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Vascular endothelial growth fa ...... n human primary solid cancers.
@en
Vascular endothelial growth fa ...... n human primary solid cancers.
@nl
type
label
Vascular endothelial growth fa ...... n human primary solid cancers.
@en
Vascular endothelial growth fa ...... n human primary solid cancers.
@nl
prefLabel
Vascular endothelial growth fa ...... n human primary solid cancers.
@en
Vascular endothelial growth fa ...... n human primary solid cancers.
@nl
P2093
P1476
Vascular endothelial growth fa ...... in human primary solid cancers
@en
P2093
Chris Womack
Dawn Baker
Graham Sproat
Juliane M Jürgensmeier
Kirsty Ratcliffe
Martin Jenkins
Neil H James
Neil R Smith
Ruth Swann
P304
P356
10.1158/1078-0432.CCR-09-2797
P407
P577
2010-07-06T00:00:00Z